CREATE Medicines
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
$122MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
Develops AI-driven drug discovery platform for first- and best-in-class therapeutics
Pitching Hatteras Venture Partners? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room